ThermoSafe CTS InfoGraphic R1 email · ThermoSafe CTS InfoGraphic R1 email Created Date: 3/2/2017...
Transcript of ThermoSafe CTS InfoGraphic R1 email · ThermoSafe CTS InfoGraphic R1 email Created Date: 3/2/2017...
TECHNOLOGY INNOVATIONSUPPLY CHAINLOGISTICS
ASSESSING THE CURRENT AND FUTURESTATE OF CLINICAL TRIAL SUPPLIES
RESPONDENTS
In order to gain a deeper understanding of this rapidly evolving Clinical Trial Supply market, Sonoco ThermoSafe, Berlinger & Co. AG and Arena International Events Group conducted a comprehensive and forward looking survey across global regions. The survey was developed and reviewed by an advisory panel of industry experts from clinical operations, clinical trial supply logistics and packaging, as well as bio-pharma manufacturing and supply chain organizations. Surveys were conducted at all Arena International events in 2016.
ADVISORY PANEL
Global Category Leader Freight & LogisticsAstraZeneca
SVP, Strategic DevelopmentClinical Supplies Management
Executive Director, Supply ChainFibroGen
Director, Clinical Interface GroupGlaxoSmithKline
Clinical Logistics LeaderOPKO Biologics
Executive Director US Clinical ServicesPCI Clinical Services
Global Operations Director, QuickStat Global Life Science Logistics
Director of Operational ExcellenceSunovion Pharmaceuticals
NORTH AMERICA 76%
EUROPE 12%
11% ASIA
2% REST OF THE WORLD
PHARMA/BIOPHARMA 55%
PACKAGING & LOGISTICS 17%
OTHER 14%(inc. DRUG SOURCING, CRO, MEDTECH)
8% CMO/VIRTUAL MANUFACTURERS
6% CLINICAL SUPPORT/ TECHNOLOGY
RESPONDENTS BY REGION
RESPONDENT COMPANY SIZE
RESPONDENTS BY INDUSTRY
COMPANY ANNUAL REVENUE $
UP TO$50M
28% 12% 11% 24% 26%
$50M-250M
250M-$1BN
$1BN-$10BN
$10BN+
Download detailed survey report atwww.thermosafe.com/ctssurvey
TEMPERATURE CONTROLLED PACKAGING
www.arena-international.com
www.berlinger.com
www.thermosafe.com
14%
38%
LOGISTICS
DIRECT-TO-PATIENT DISTRIBUTION
TECHNOLOGY
SUPPLY CHAIN
INNOVATION
RAW MATERIAL toDRUG SUBSTANCE
DRUG SUBSTANCEto DRUG PRODUCT
DRUG PRODUCT toPRIMARY PACKAGING
PRIMARY PACKAGINGto FINISHED GOODS
55%
45%
59%
41%
68%
32%
71%
29%
DISTRIBUTION PATH/DRUG SUPPLY STAGE
LOGISTICS METHOD UTILIZED BY DISTRIBUTION PATH/DRUG SUPPLY STAGE
OUTSOURCED IN-HOUSE
S AMERICA
10%22%
68%
C AMERICA
14%
34%
52%
ASIA
22%
35%
42%
E EUROPE
33%
31%
36%
W EUROPE
55%
33%
11%N AMERICA
72%
20%8%
LOGISTICS CHALLENGE BETWEEN DEPOT TO CLINICAL SITES BY REGION
5 - CHALLENGING
3 - MODERATE
1- EASY
AREAS OF CONCERN ASSOCIATED WITH IMPORT BROKERS
COSTS
16%
32%
52%
VISIBILITY
22%
26%
53%
BRIBERY/CORRUPTION
43%
24%
30%
5 - VERY CONCERNED
3 - CONCERNED
1- NOT CONCERNED
32% COURIER
28% CRO
22% DEPOT
14% INTERNALLY MANAGED
4% OTHER
TYPE OF IMPORT BROKER USED
USE OF DTP SHIPMENTS FROM ADEPOT/CLINICAL SITE TO PATIENTS HOME
% LIKELIHOOD OF USING DTP IN FUTURE(NEXT 12 -18 MONTHS)
% REASONS FOR SHIPPING DTP % RISKS OF SHIPPING DTP
24% YES
76% NO
5VERY
LIKELYNOT
LIKELY
4%
4
6%
3
23%
2
5%
1
60%
IMPROVE PATIENTRETENTION BY
INCREASINGCONVENIENCE
PATIENT POOL SO WIDELYDISPERSED THAT
STANDARD POOLINGOPTIONS DO NOT APPLY
IMPROVECOMMUNICATION
DIRECTLY WITHPATIENTS
REDUCE CLINICALSUPPLY COSTS
OTHER 13%
17%
19%
LOSS OF COLDCHAIN CONTROL
PATIENT ADHERENCE TOCLOSE REQUIREMENTS
EMERGENCYREPLENISHMENT DUE
TO MISHANDLING OFINVESTIGATIONAL MATERIALS
LOST MATERIALS THROUGHSHIPPING MISTAKES
OTHER
28%
25%
23%
18%
6%
SUPPLY CHAIN TECHNOLOGIES USED
INTERACTIVERESPONSE
SYSTEM
MICROSOFTOFFICETOOLS
VENDORINVENTORY/
DISTRIBUTIONSYSTEM
TEMPERATUREMONITORINGDATABASE
CENTRALINVENTORY/
DISTRIBUTIONSYSTEM
FORECASTINGSYSTEM FOR
FINISHEDGOODS
OTHER(MISC DBASE/
MANUFACTURINGSYSTEM)
25% 24% 13% 13% 10% 8% 7%
PLANS TO EXPAND USE OFMOBILE TECHNOLOGY IN NEXT 1-2 YEARS
LEVEL OF MOBILE TECHNOLOGY USE AT WORK(EXCLUDES EMAIL & VOICE CALLS)
% OF RESPONDENTS
USE OF MOBILE TECHNOLOGY (EXC. EMAIL/CALLS)
31% NO
69% YES
Used<10%
55%
10%-25%
17%
26%-50%
12%
51%-75%
7%
76%+
9%
4% 16% 42% 32% 3% 4%
100%REACTIVE
100%PROACTIVE
50% REACTIVE,50% PROACTIVE
80% REACTIVE,20% PROACTIVE
80% PROACTIVE,20% REACTIVE OTHER
DEGREE OF IMPACT TOOLS HAVE ON SUCCESSFUL FORECASTING OF CLINICAL TRIAL SUPPLIES
RELIABLECRO WITH
GOODCOLLABORATION
87%
6%8%
RELIABLEDISTRIBUTER& PACKAGING
VENDOR
85%
RELIABLEMANUFACTURING
PRODUCTION
20%
DYNAMICIRT
SYSTEM
15%
OTHER
33%
TRIALCOMPLEXITY/
SIZE OFPATIENT POOL
5%EXCEL
SPREADSHEET
13%
SIMULATIONSOFTWARE
30%10%5% 6%
74% 69% 67% 65% 61% 47%
17% 31%25%
23%
MORE HELPFUL HELPFUL LESS HELPFUL
LEVEL OF INNOVATION
HOW INNOVATIVE IS YOUR ORGANIZATION?
3% - 1 (NOT INNOVATIVE)
10% - 2
39% - 3 (INNOVATIVE)
26% - 4
22% - 5 (VERY INNOVATIVE)
MAIN BARRIERS TO DRIVING INNOVATION AT YOUR ORGANIZATION
COST
25%
TIME
18%
PEOPLE
18%
RISKAVOIDANCE
& PASTFAILURES
15%
REGULATORYCONCERNS
9%
TOOLS
7%
CHANGECONTROL
DOCUMENTATION/PROCESSUPDATE
7%
NOBARRIERS
TOINNOVATION
2%